Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
調査の概要
状態
詳細な説明
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Argenteuil Cedex、フランス
- Research Site
-
Belley、フランス
- Research Site
-
Castelmaurou、フランス
- Research Site
-
Cavaillon、フランス
- Reserach Site
-
Les Mureaux、フランス
- Research Site
-
Lille、フランス
- Research Site
-
Marseille、フランス
- Research Site
-
Montpellier、フランス
- Research Site
-
Nimes Cedex、フランス
- Research Site
-
Obernai、フランス
- Research Site
-
Paris、フランス
- Research Site
-
Rennes、フランス
- Research Site
-
Saintes Cedex、フランス
- Research Site
-
Sens、フランス
- Research Site
-
St Dizier、フランス
- Research Site
-
St Egreve Cedex、フランス
- Research Site
-
Toulouse、フランス
- Research Site
-
Tours、フランス
- Research Site
-
Ussel Cedex、フランス
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- New patients treated with Xeroquel XR
- Patients aged 18 years and over
- Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
Exclusion Criteria:
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
- Pregnant women
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Main study population
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months. |
Schizophrenia SoC sample
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
|
Bipolar SoC sample
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Descriptive analysis of variables related with how the drug is prescribed and used by the patient.
時間枠:At inclusion
|
Variables related with how the drug is prescribed and used by the patient [doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments] are going to be described.
|
At inclusion
|
Description of patient's socio-demographics profile.
時間枠:At inclusion
|
Age, gender, educational and professional status, co-habitation are going to be described.
|
At inclusion
|
Descriptive analysis of medical history.
時間枠:At inclusion
|
Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.
|
At inclusion
|
Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).
時間枠:At inclusion
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
At inclusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.
時間枠:From baseline to 12 months
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
From baseline to 12 months
|
Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.
時間枠:From baseline to 12 months
|
From baseline to 12 months
|
|
Descriptive analysis of the treatment changes: drug switches.
時間枠:From baseline to 12 months
|
From baseline to 12 months
|
|
Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.
時間枠:From baseline to 12 months
|
From baseline to 12 months
|
|
Change in Body Mass Index (BMI).
時間枠:From baseline to 12 months
|
From baseline to 12 months
|
|
Laboratory tests- cholesterol.
時間枠:From baseline to 12 months
|
Blood test- cholesterol.
|
From baseline to 12 months
|
Descriptive analysis of all adverse events.
時間枠:From baseline to 12 months
|
From baseline to 12 months
|
|
Relapses (only for the schizophrenia subpopulation).
時間枠:From baseline to 12 months
|
New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.
|
From baseline to 12 months
|
Laboratory tests- glycemia.
時間枠:From baseline to 12 months
|
Blood test- glycemia.
|
From baseline to 12 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Bruno FALISSARD, Pr、Paris
- 主任研究者:Pierre-Michel LLORCA, Pr、Clermont-Ferrand
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- NIS-NFR-SER-2012/1
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。